Ascendiant Capital Maintains Buy Rating for Plus Therapeutics and Raises Target Price

Summary

Ascendiant Capital maintained a buy rating for Plus Therapeutics and increased the target price from $19.00 to $20.00. Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing treatments for recurrent glioblastoma and leptomeningeal metastases. Their main candidate drug, rhenium (186Re) obisbemeda, is targeted at central nervous system cancers.Stock Star

Impact Analysis

The event is at the company level, focusing on Plus Therapeutics. The rating and target price adjustment by Ascendiant Capital indicates confidence in the company’s prospects, particularly regarding its drug candidates. First-order effects include increased investor interest and potential stock price appreciation due to the revised target price reflecting anticipated success in drug development. Second-order effects may involve broader interest in the biotechnology sector, especially companies developing innovative cancer treatments. Investment opportunities could arise from trading Plus Therapeutics stock, particularly for investors who believe in the company’s growth prospects as signaled by the target price revision.Stock Star